M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT02595931)

🧪 Interventions in This Study

• Berzosertib (DRUG)
• Irinotecan Hydrochloride (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (23 Sites)

• Los Angeles General Medical Center — Los Angeles, California
• USC / Norris Comprehensive Cancer Center — Los Angeles, California
• Stanford Cancer Institute Palo Alto — Palo Alto, California
• Keck Medical Center of USC Pasadena — Pasadena, California
• University of California Davis Comprehensive Cancer Center — Sacramento, California
• UCSF Medical Center-Mount Zion — San Francisco, California
• Smilow Cancer Center/Yale-New Haven Hospital — New Haven, Connecticut
• Yale University — New Haven, Connecticut
• UF Health Cancer Institute - Gainesville — Gainesville, Florida
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts
• Brigham and Women's Hospital — Boston, Massachusetts
• Beth Israel Deaconess Medical Center — Boston, Massachusetts
• Dana-Farber Cancer Institute — Boston, Massachusetts
• Wayne State University/Karmanos Cancer Institute — Detroit, Michigan
• Siteman Cancer Center at Saint Peters Hospital — City of Saint Peters, Missouri
• Siteman Cancer Center at West County Hospital — Creve Coeur, Missouri
• Washington University School of Medicine — St Louis, Missouri
• Siteman Cancer Center-South County — St Louis, Missouri
• Siteman Cancer Center at Christian Hospital — St Louis, Missouri
• UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
• UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania
• Vanderbilt Breast Center at One Hundred Oaks — Nashville, Tennessee
• Vanderbilt University/Ingram Cancer Center — Nashville, Tennessee

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Colorectal Carcinoma

• Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer — Columbus, Ohio
• Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer — Phoenix, Arizona
• TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer — Elizabeth, New Jersey
• BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma — Birmingham, Alabama
• HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization — Rochester, Minnesota

Explore by condition: All Metastatic Colorectal Carcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.